“On Pfizer's first-quarter earnings call, CEO Albert Bourla was optimistic that in 2029, the company will begin a five-year period of strong growth, with revenue growth rates in the high…”
“Bourla said the company is planning to begin 20 pivotal studies this year and anticipates four regulatory decisions, calling 2026 "a pivotal year for R&D."”
“We intend to maintain and over time, grow our dividend as we continue to delever and build long-term value.”
“He replied that Pfizer will always explore merger and acquisition opportunities, but the company isn't planning to pursue a large-scale merger. Bourla added that the disruption of a mega…”